Active Ingredient(s): Odevixibat
FDA Approved: * July 20, 2021
Pharm Company: * ALBIREO
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Bylvay Overview

Odevixibat, sold under the trade name Bylvay, is a medication for the treatment of progressive familial intrahepatic cholestasis (PFIC).[1][4] It is taken by mouth.[1] The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver).[4] Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT).[4][5&am...

Read more Bylvay Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Bylvay Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 0.4mg, 1.2mg
  • Capsule, Pellets: 0.2mg, 0.6mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Odevixibat or a similar ingredient: (1 result)